The proteins of the BCL2 family are key regulators of apoptosis that control the permeability of the mitochondrial outer membrane to cytochrome c (cyt c) and other apoptotic factors. They have an important role in the formation of tumors and in cellular responses to anticancer treatments [1] [2] [3] . The members of the family are classified into three subgroups: (i) antiapoptotic proteins, such as BCL2 or BCL XL , that inhibit apoptosis by binding the proapoptotic members; (ii) proapoptotic proteins, such as BCL2-associated X protein (BAX) or BCL2-antagonist/killer 1 (BAK), that are believed to participate directly in permeabilization of the mitochondrial outer membrane (MOM); and (iii) BH3-only proteins, which are further classified as direct activators or sensitizers/derepressors. Direct activators, such as BID, activate BAX and BAK for MOM permeabilization 4 , whereas sensitizer/derepressor BH3-only proteins induce apoptosis by binding to and neutralizing antiapoptotic BCL2 members 5 . Under normal conditions BID is inactive in the cytosol, but in the presence of apoptotic stimuli it is proteolytically cleaved to give an active truncated form called tBID that induces cyt c release 6 .
a r t i c l e s
The proteins of the BCL2 family are key regulators of apoptosis that control the permeability of the mitochondrial outer membrane to cytochrome c (cyt c) and other apoptotic factors. They have an important role in the formation of tumors and in cellular responses to anticancer treatments [1] [2] [3] . The members of the family are classified into three subgroups: (i) antiapoptotic proteins, such as BCL2 or BCL XL , that inhibit apoptosis by binding the proapoptotic members; (ii) proapoptotic proteins, such as BCL2-associated X protein (BAX) or BCL2-antagonist/killer 1 (BAK), that are believed to participate directly in permeabilization of the mitochondrial outer membrane (MOM); and (iii) BH3-only proteins, which are further classified as direct activators or sensitizers/derepressors. Direct activators, such as BID, activate BAX and BAK for MOM permeabilization 4 , whereas sensitizer/derepressor BH3-only proteins induce apoptosis by binding to and neutralizing antiapoptotic BCL2 members 5 . Under normal conditions BID is inactive in the cytosol, but in the presence of apoptotic stimuli it is proteolytically cleaved to give an active truncated form called tBID that induces cyt c release 6 .
Despite intense research, the molecular mechanisms of action of the proteins of the BCL2 family remain controversial. At the center of the debate, two questions seem to be crucial. The first question concerns the translocation to the MOM that most members of the family experience during apoptosis activation, and the second concerns the interactions between them, which determine whether apoptosis is induced. Three models have been proposed to explain how the BCL2 proteins regulate apoptosis 7 . The 'indirect' model states that the antiapoptotic members are bound to intrinsically active BAX and BAK, thus blocking their action and ensuring cell survival. During apoptosis, the BH3-only proteins are stimulated and bind to the antiapoptotic proteins, thus liberating BAX and BAK to induce cyt c release [8] [9] [10] . The 'direct activation' model states that BAX and BAK are normally inactive and that during apoptosis they are activated by the BH3-only proteins to promote MOM permeabilization 11, 12 . In this scenario the antiapoptotic proteins block cell death by binding and neutralizing BH3-only proteins. Recent data support a third alternative, the 'embedded together' model, which assumes that insertion into the MOM during apoptosis affects the affinities between the different BCL2 proteins and exposes new interaction surfaces 4, 13 . As the role of the membrane has been underestimated until recently, there is a lack of experimental data for the interaction of these proteins in membranes and, as a result, their nature and relative importance remain unknown.
To establish the importance of the MOM, it is essential to examine the strength of the interactions between BCL2 proteins in aqueous and lipid environments. For this purpose, a chemically defined system that avoids unwanted effects of unknown factors is required. Cell-free systems have been shown to reproduce satisfactorily the features of the BCL2 proteins observed during apoptosis 4, 14, 15 . We performed a comparative and quantitative analysis of the nature and strength of the interactions between human BID or tBID and human BCL XL ∆Ct in aqueous solution and in the membrane using reconstituted systems. We used a new variant of fluorescence cross-correlation spectroscopy (FCCS) to demonstrate that active tBID, but not fulllength BID, binds to BCL XL ∆Ct in solution and that this interaction is strongly enhanced in the membrane. This finding sheds light on a key event in MOM permeabilization, that is, the contribution of the membrane environment to the modulation of interactions between BCL2 members. Altogether, our data suggest that BCL XL neutralizes tBID mainly at the membrane, and they support a model in which membrane association represents an additional regulatory stage for the control of MOM permeabilization.
RESULTS tBID and BCL XL ∆Ct induce each other's binding to membranes
Because chemically defined systems are necessary to quantify the interactions between tBID and BCL XL under controlled conditions, we used a cell-free reconstituted system with highly purified proteins and model membranes. We selectively mutated recombinant tBID and BCL XL ∆Ct to allow fluorescent labeling at single cysteines with Alexa647 and Alexa488, respectively. The mutations introduced and the positions of labeling in the proteins are highlighted in their structures, which are shown in Figure 1a ,b. To ensure that our system mimics as faithfully as possible the natural process, we checked that the labeled proteins, namely tBID red and BCL XL ∆Ct green , retained their ability to induce or inhibit cyt c release from isolated mitochondria at concentrations comparable to the unlabeled wild-type versions (Fig. 1c,d) .
We investigated the membrane-binding properties of tBID red and BCL XL ∆Ct green in giant unilamellar vesicles (GUVs). These are model membrane systems that offer the advantage of freestanding bilayers with sizes ranging from a few to hundreds of micrometers, therefore being suitable for optical microscopy and fluorescence correlation spectroscopy (FCS).
tBID red did not bind to vesicles containing phosphatidylglycerol (Fig. 2a) , but it showed specific binding to GUVs containing cardiolipin (Fig. 2b) , in accordance with previous reports on the lipidmediated selectivity of tBID binding to lipid membranes [16] [17] [18] [19] [20] [21] . Notably, tBID red associated with GUVs that contained tethered BCL XL ∆Ct (see below), even in the absence of cardiolipin (Fig. 2c ) (see control without BCL XL ∆Ct in Supplementary Fig. 1 ).The active, cleaved form (tBID) was required for membrane binding. Full-length BID labeled with Bodipy did not show binding to cardiolipin-containing vesicles under similar conditions (Fig. 2d) .
Next we analyzed membrane binding of BCL XL ∆Ct green . At neutral pH, the protein remained in the aqueous phase (Fig. 2e) but bound to anionic vesicles at acidic pH 22 (Fig. 2f) . Moreover, we tethered BCL XL ∆Ct green to GUVs at neutral pH via its histidine tag when small amounts of the lipid derivative DOGS-NTA-Ni (Ni-lipid) were incorporated into GUVs (Fig. 2g) . This noncovalent association with the lipid moiety mimics the membrane-anchored state of fulllength BCL XL via its C-terminal transmembrane helix 23 . In addition, tBID induced BCL XL ∆Ct green association with cardiolipin-containing GUVs at neutral pH (Fig. 2h) . This indicates that hydrophobic fragments of BCL XL besides the absent C terminus also participate in the tBID-induced membrane interaction. These results are in accordance with those that previously suggested a role for BCL XL helices 5 and 6 in the membrane-binding process 24 . The fluorescence spectrum of BCL XL ∆Ct in presence of tBID and lipid vesicles supports this observation (Supplementary Fig. 2 ). As tBID has no tryptophan residues and its contribution to the spectrum is negligible, the spectral blue shift obtained for BCL XL ∆Ct in the presence of tBID and membranes is indicative of a transition of BCL XL ∆Ct to a more hydrophobic environment, probably accompanied by a conformational change. The effect of tBID is supported by the absence of spectral changes for BCL XL ∆Ct alone in the presence of large unilamellar vesicles (LUVs).
tBID and BCL XL ∆Ct cooperate in membrane permeabilization tBID has been shown to induce a conformational change to the membrane-bound form of the BCL XL homolog BCL2 that is related to the formation of small pores in the lipid membrane 23 . To investigate whether BCL XL shows a similar behavior, we used the GUV approach. We added Alexa543 free dye to the outside solution of the GUV samples containing tBID red and/or BCL XL ∆Ct green . We monitored The advantage of this strategy is that protein binding, membrane permeabilization and vesicle integrity can be accessed simultaneously. Moreover, additional information, for example, about heterogeneities in the permeabilization process, is obtained through comparison with bulk measurements 25, 26 . Because membrane permeabilization is followed at the level of individual vesicles, the permeabilization kinetics of single GUVs can be measured and compared to those of other vesicles and to the kinetics of ensemble sample permeabilization.
We imaged the effect of tBID red and/or BCL XL ∆Ct green on the permeability of GUVs for 4 h at room temperature (20 °C) ( Fig. 3a and Supplementary Movie 1). Over that time, most of the vesicles were permeabilized in the samples containing both tBID red and BCL XL ∆Ct green . Single GUV permeabilization was complete in less than 2 min, indicating fast kinetics. We analyzed the poreforming activity of the proteins by quantifying the permeabilized GUVs. Binding of tBID red or BCL XL ∆Ct green individually to the lipid membranes caused substantial permeabilization of the vesicles when compared to control samples or to nonbinding conditions (Fig. 3b) . However, the percentage of permeabilized liposomes in the presence of both tBID red and BCL XL ∆Ct green reached 60% for phosphatidylcholine:cardiolipin (8:2) and 85% for phosphatidylcholine: Ni-lipid (99:1). This is nearly two times higher than the sum of the activities of the individual proteins for those lipid compositions and supports a synergistic effect of tBID and BCL XL ∆Ct on their membrane-binding and/or permeabilizing activities. The increase in the percentage of permeabilized vesicles with time and the synergistic effect at several protein concentrations are shown in Figure 3c and 3d, respectively.
Binding between tBID and BCL XL ∆Ct is enhanced in membranes
The autocorrelation of the FCS data obtained for tBID red and BCL XL ∆Ct green allows quantification of their concentrations and diffusion properties. Furthermore, the cross-correlation analysis of tBID red and BCL XL ∆Ct green diffusion through the focal volume of the microscope provides quantitative information about protein-protein binding and can be used for measurements both in solution and in lipid membranes 27, 28 . A scheme of the experimental setup used is depicted in Figure 4a .
Total tBID red or BCL XL ∆Ct green , comprising free protein and protein in the complex, gave rise to the autocorrelation curves in Figure 4b ,c (orange and green lines, respectively). However, when tBID red and BCL XL ∆Ct green interacted and diffused as a complex, the fluorescence fluctuations were similar in both channels and contributed to the amplitude of the cross-correlation curve (blue line, Fig. 4b,c) . Thus, a larger cross-correlation amplitude indicates a higher concentration of tBID-BCL XL ∆Ct complexes in the sample (Supplementary Methods).
At a concentration of 100 mM in PBS of each protein, we measured ~15% cross-correlation (Fig. 4b) , which indicates the formation of tBID-BCL XL ∆Ct complexes in solution. Notably, we did not observe any cross-correlation for full-length BID red and BCL XL ∆Ct green at concentrations up to 330 nM ( Supplementary Fig. 3 ). These results strongly suggest that activation of BID by proteolytic cleavage is necessary to promote binding to BCL XL .
To overcome the technical difficulties associated with the quantification of complex formation in lipid membranes, we used a new variant of FCS named two-color two-focus scanning FCS 29 (see Online Methods). We added tBID red and BCL XL ∆Ct green to a suspension of GUVs composed of phosphatidylcholine:cardiolipin (8:2) and incubated the mixture for 2 h at room temperature to ensure equilibrium conditions before measuring scanning FCS across the membrane plane of giant liposomes containing the bound proteins (Fig. 4c) a r t i c l e s those used in solution) to the GUV suspension provided a 40% cross-correlation (higher than detected in solution), which showed that the interaction between the two proteins is enhanced by the presence of lipid membranes.
The amount of particles forming tBID-BCL XL ∆Ct complexes can be calculated from the ratio of cross-correlation and autocorrelation amplitudes, allowing the estimation of effective dissociation constants. From the FCCS data measured at different protein concentrations (Fig. 4d) , we obtained a K d of 200 ± 20 nM (120 ± 10 molecules per µm 3 ) (± s.d.) for complex formation in solution ( Supplementary  Fig. 4 and Supplementary Methods). This value is on the same order of magnitude as the K d reported in the literature for BH3 peptides 8, 30, 31 . However, in the presence of lipid membranes, we obtained maximum cross-correlation (which is reduced to 45% because of partial protein labeling) within the statistical variance at all concentrations measured ( Fig. 4e; Supplementary Table 1) , suggesting that the affinity between tBID and BCL XL ∆Ct is so high that we were in saturation under the conditions tested. This allows us to infer that the K d in the membrane will be lower than 10 molecules per µm 2 and demonstrates a higher affinity between tBID and BCL XL ∆Ct embedded in lipid membranes when compared with the complex in solution.
From the respective autocorrelation curves, we calculated that tBID in solution diffused at 143 ± 9 µm 2 s −1 (± s.d.), whereas BCL XL ∆Ct had a diffusion coefficient of 78 ± 10 µm 2 s −1 , in agreement with their respective molecular weights (focal volume calibrated with Atto655 (ref. 32 ) and Alexa488 (ref. 33) ). Under conditions of complex formation with a cross-correlation of 30%, their average mobility decreased to 53 ± 3 µm 2 s −1 for tBID and to 58 ± 6 µm 2 s −1 for BCL XL ∆Ct. As expected, we deduced values that were from one to two orders of magnitude slower from the experiments performed in the presence of lipid membranes with two-focus scanning FCS. For the individual proteins, we obtained diffusion coefficients of 5.0 ± 0.3 µm 2 s −1 and 4.8 ± 0.7 µm 2 s −1 for tBID and BCL XL ∆Ct, respectively. When tBID and BCL XL ∆Ct formed complexes in the lipid bilayer, these values decreased to 4.4 ± 0.6 µm 2 s −1 . As the diffusion coefficient of a particle is related to its hydrodynamic radius 34 , the decrease in mobility observed in the presence of tBID-BCL XL ∆Ct complexes is in good agreement with the size increase associated with complex formation. However, in the case of two-dimensional diffusion in membranes, the diffusion coefficient scales with the logarithm of the hydrodynamic radius 35 , which accounts for the weaker effect observed.
Inhibition of tBID-BCL XL ∆Ct complexes in membranes
The heterodimerization of tBID with BCL XL in solution is believed to happen via insertion of the BH3 domain of tBID into the hydrophobic cleft formed by the BH1, BH2 and BH3 regions of BCL XL . This interaction can be reproduced with peptides derived from the BH3 region of BH3-only proteins that bind to the hydrophobic cleft of BCL XL and other BCL2 homologs 36, 37 . As a negative control for our crosscorrelation experiments and to explore whether the protein-protein interaction surfaces implicated in tBID-BCL XL complex formation are similar in solution and in lipid membranes, we evaluated the ability of a BH3-derivative peptide (BidBH3) to compete for such interactions. In FCCS experiments in solution, addition of an excess of nonfluorescent BidBH3 peptide to the tBID-BCL XL ∆Ct complex lead to a decrease in the cross-correlation percentage to values close to zero, indicating competitive disruption of the complex (Fig. 5a) . Similarly, unlabeled, wild-type tBID at a concentration of ~1 µM can also totally displace the interaction between tBID red and BCL XL ∆Ct green after 3 h (Fig. 5b) . The kinetics of inhibition was similar to that of complex formation (Fig. 5c) . Because of solubility problems, we could not exceed ~1 µM unlabeled tBID in these experiments, which decreased the inhibition rate when compared to the peptide. However, when we assayed BidBH3, also at ~1 µM, the extent and rate of inhibition were comparable to those of unlabeled tBID (data not shown).
In contrast, when we added a mixture of tBID red , BCL XL ∆Ct green and an excess of BidBH3 to a suspension of GUVs, cross-correlation values in the membrane were similar to those of control samples without the BH3 peptide (Fig. 5d) . This resistance to BidBH3 indicates that, even in the presence of the peptide, tBID and BCL XL ∆Ct bind to the membrane and form a stable complex. The inability of 
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BidBH3 to compete for the complex in membranes could be related to its low membrane affinity or to the different nature of tBID-BCL XL interactions. To distinguish between these possibilities, we used a version of the BidBH3 peptide containing a hexahistidine (His 6 )-tag on the C terminus (BidBH3His) that can be efficiently targeted to membranes containing Ni-lipid. This peptide has been shown to potently activate BAX 38 . Notably, when we added BidBH3His in a large excess to GUVs containing interacting tBID and BCL XL ∆Ct, the percentage of complexes remained unaltered. Only when added simultaneously with tBID and BCL XL ∆Ct to the GUVs suspension could the BidBH3His peptide partially disrupt the complex between the proteins (Fig. 5e) . A mutant peptide that cannot interact with BCL XL (BidBH3His MUT ) did not affect complex formation under the same conditions (Fig. 5e) . These results indicate that the interactions between tBID and BCL XL in solution and within lipid membranes are not equivalent.
To test whether complex formation in the membrane could be totally disrupted, we again used unlabeled tBID. We incubated a suspension of GUVs containing tBID red -BCL XL ∆Ct green complexes with a molar excess of unlabeled tBID (Fig. 5f,g) . The cross-correlation amplitude became almost zero (Fig. 5g) . These observations indicate that unlabeled tBID can bind to BCL XL ∆Ct green and displace tBID red from the complex, which also means that complex formation in the membrane is reversible.
Estimation of the number of particles in the membrane focal area showed that the excess of unlabeled tBID decreased the number of dual-color fluorescent tBID-BCL XL ∆Ct particles but also influenced the membrane binding of tBID red and BCL XL ∆Ct green (Fig. 5h) . The number of tBID red molecules associated with the membrane decreased, indicating that tBID binding to lipid bilayers is reversible and that only a finite number of binding sites is allowed. The increase in the total number of BCL XL ∆Ct green particles bound to the membrane indicates that tBID induces BCL XL ∆Ct association with lipid membranes.
DISCUSSION
The physiological relevance of the effect of BH3-only proteins on prosurvival BCL2 members during apoptosis has been described 9 , although the molecular mechanism has not been clarified. Our imaging and FCS results show that tBID and BCL XL ∆Ct enhance each other's binding to lipid membranes. One of the most relevant findings of this study is that tBID promotes BCL XL binding to cardiolipincontaining vesicles, in agreement with recent biochemical experiments 39 and providing a molecular basis for the translocation of BCL XL to the MOM during apoptosis 40 . We found that the C-terminal transmembrane region of BCL XL is not strictly necessary for membrane binding, although it probably contributes to it. According to our observations, tBID would induce a conformational change in BCL XL in the presence Moreover, tBID also associated with GUVs containing tethered BCL XL , even in the absence of cardiolipin. This may have physiological implications, because a portion of prosurvival BCL2 members are located in cellular membranes other than the MOM. It is reasonable to postulate that this could be used by cells to decrease free tBID molecules that could reach the MOM and induce apoptosis 42 . It could also be that tBID binding to prosurvival BCL2 proteins in the endoplasmic reticulum inactivates their protective action and contributes to apoptosis induction 43 . Moreover, our quantitative analysis reveals that tBID binding to cardiolipin-containing membranes is reversible and probably reaches saturation. This suggests that cardiolipin acts as a mitochondrial receptor for tBID. However, stoichiometrically the interaction does not seem to be one to one, and other factors, such as increased membrane tension, may impair further protein insertion into the lipid bilayer. What is more interesting is that this implies that tBID membrane binding could be blocked by cardiolipinbinding competitors. Future work will be required to determine whether similar behavior can be observed in vivo and whether it affects apoptosis, hence constituting a new therapeutic target for apoptosis regulation.
Imaging single-vesicle permeabilization induced by tBID and BCL XL ∆Ct showed that membrane integrity is maintained and that the process follows fast kinetics once it starts. The cooperative effect observed is in agreement with the high affinity between the two proteins in lipid membranes measured by FCCS. This implies that complex formation alters membrane permeability, as reported for tBID and BCL2 (ref. 23 ). This activity is difficult to reconcile with the antiapoptotic function of BCL XL and BCL2, but in the context of the 'embedded together' model prosurvival members behave as defective, dominant-negative BAX molecules, able to insert and alter the membrane permeability but unable to oligomerize and release cyt c 13, 39 .
In this study, we used a quantitative approach to examine binding of BID and tBID to BCL XL ∆Ct in a biochemically well-defined model system. A new FCCS strategy allowed us to evaluate dynamic protein-protein interactions in lipid bilayers and, for the first time, we estimated effective dissociation constants for tBID-BCL XL ∆Ct complexes in solution and in the membrane. Our results show that tBID and BCL XL interact in both environments, and they reveal the strong effect of the membrane on their effective affinity, which had previously been underestimated. The molecular details behind this effect are related to the reduction of dimensionality in the system from a three-dimensional solution to the two-dimensional plane of the membrane, which increases the collision probability, and the translocation into an anisotropic, hydrophobic environment, which induces structural reorganizations and modifies the thermodynamics of tBID-BCL XL ∆Ct interactions. Our observations have implications for the biological functions of tBID and BCL XL , as they strongly suggest that the most relevant interaction between these proteins, and probably between other homolog proteins of the family, occurs in the membrane, as recently reported for BAX and tBID 4 . Similar membrane-based mechanisms have been proposed in other signaling processes, and indeed this could be a general strategy used by cells to increase interactions between proteins and to modulate downstream cellular responses [44] [45] [46] . The strong effect of the membrane on tBID-BCL XL complex formation raises other questions, such as the role of lipids in the function of the BCL2 proteins, the structures of these proteins in the membrane-bound state or the nature of the interaction surfaces in the lipidic environment.
The absence of interactions between full-length BID and BCL XL ∆Ct under the conditions investigated links the activation of BID and its role as an apoptosis inducer to the promotion of its interactions with BCL XL and probably other members of the BCL2 family.
A BH3-derived Bid peptide (BidBH3) induced dissociation of the tBID-BCL XL ∆Ct complex in solution, but not when the complex was stabilized in lipid membranes. Even when BidBH3 efficiently shifts the equilibrium in solution, tBID and BCL XL ∆Ct translocated to the lipid bilayer and formed complexes. To ensure accessibility of the peptide to the membrane, we used a His 6 -tagged version (BidBH3His) that can be tethered to membranes containing Ni-lipid and has been shown to efficiently activate BAX 38 . However, membrane-targeted BidBH3His could not disrupt previously formed tBID-BCL XL ∆Ct complexes within membranes and was able to block complex formation only partially when added simultaneously with tBID and BCL XL ∆Ct-that is, before complex formation. Notably, these findings indicate the existence of two populations of tBID and BCL XL ∆Ct with different susceptibility to the BH3 peptide in membranes. On the basis of the different membrane-bound states proposed for BCL2 proteins 24 , it is tempting to speculate that BidBH3His could bind to membraneassociated BCL XL ∆Ct but not to the membrane-inserted form, which in turn can still interact with tBID. This could be explained in terms of the low hydrophobicity of BidBH3His, which would not be able to insert into the lipid bilayer and displace the more hydrophobic tBID from the complex with BCL XL . Furthermore, the existence of alternative binding sites for the membrane-inserted proteins that further stabilize the complex cannot be ruled out. The differences observed with BAX activation by BidBH3His could be based on the induction of BAX association with the membrane by the peptide. In such a situation, BAX would then insert into the membrane and form pores, for which the peptide would no longer be necessary.
Given the importance of BCL2 targeting in cancer therapy, these findings have important consequences for the design of inhibitors of BCL2 prosurvival proteins 47 . Membrane-inserted tBID-BCL XL seems to constitute an additional drug target that cannot be inhibited with BH3 mimetics and related molecules, but probably can be with more lipophilic compounds. Indeed, the small molecule ABT-737 and PUMA induced apoptosis by releasing tBID from complexes with prosurvival BCL2 members within mitochondria, which was associated with a 'direct activator:prosurvival BCL2 a r t i c l e s protein:sensitizer/derepressor' network 48 . Also, the proapoptotic effect of the small molecule obatoclax has been linked to its ability to block MCL1 in the membrane 49 . Notably, the experimental approach shown here constitutes a powerful method to investigate quantitatively the molecular mechanism of BCL XL inhibitors. The contribution of the membrane to the modulation of the interactions between BCL2 proteins that is shown here supports the 'embedded together' hypothesis. It constitutes an additional regulatory step of apoptosis and reveals a more complex scenario, with multiple parallel equilibriums that affect the final event of MOM permeabilization. This is consistent with our observations that BidBH3His cannot totally dissociate the tBID-BCL XL ∆Ct complex when it is stabilized in lipid membranes, indicating that the protein-protein interactions in solution and in the membrane are not equivalent. Understanding the molecular mechanisms of the BCL2 proteins involves detailed knowledge of their interaction networks. Therefore, introduction of BAX and derepressor/sensitizer BH3-only proteins in the system, and quantification of their relative affinities in solution and in lipid membranes, will help to identify which interactions within the family are favored and, thus, crucial for MOM permeabilization regulation.
Altogether, the data reported here support a new model in which BID cleavage acts as a switch that allows its interaction with BCL XL and probably other multidomain BCL2 proteins (Fig. 6) . The active fragment tBID can then bind BCL XL in solution and induce its translocation into the MOM, which is accompanied by conformational changes and alteration of the membrane permeability. tBID also binds BCL XL in the membrane, where their effective affinity is greatly enhanced so that BCL XL can inhibit tBID more efficiently. As a consequence, neutralization of tBID's action by BCL XL happens mainly within the membrane. This scenario also implies that tBID promotes BCL XL 's inhibitory activity, which may constitute a control mechanism to avoid unwanted MOM permeabilization while ensuring rapid induction of apoptosis once tBID is displaced by derepressor BH3-only proteins.
In summary, our findings show the active role of the membrane in modulating the interactions between tBID and BCL XL . This has important consequences for the current understanding of apoptosis regulation, as we have introduced in a new model for BCL XL inhibition of tBID. We found unanticipated strong interactions between tBID and BCL XL in lipid membranes, as compared to the interactions in solution. This was possible thanks to unprecedented quantitative binding studies with full-length BCL2 proteins in both environments. Our results link the cleavage of BID to a change in its affinity for BCL XL that allows complex formation. The findings that tBID and BCL XL induce each other's binding to membranes and that they cooperate to induce membrane permeabilization are in good agreement with the formation of a stable complex within the membrane, where, as a consequence, the main inhibition of tBID by BCL XL takes place. Notably, the distinct susceptibility to BH3 peptides in solution and tethered to membranes demonstrates the existence of different tBID-BCL XL complex conformations in both environments. Our new experimental approach offers further perspectives on the molecular mechanisms of interactions at interfaces. The quantitative analysis based on FCS constitutes a promising strategy for a better understanding of the regulation of BCL2 proteins and for the investigation of protein-protein interactions within membranes in general, an issue that has proved extremely challenging so far.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
ONLINE METHODS
Protein preparation. We prepared fluorescently labeled human tBID as described 52 , from BID cDNA in pET15b with a single cysteine at position 64 in the tBID fragment, and labeled it with Alexa647 maleimide (Invitrogen). We purified full-length BID with the same protocol as that used for tBID, but from a cDNA with C15S and C28S mutations, and labeled it with Bodipy or Alexa647 maleimide.
We introduced mutations S2C and C151S in human BCL (BCL XL ∆Ct) in a modified pET15b vector. We overexpressed the protein in Escherichia coli. For purification, we used a His-trap HP column (Amersham Biosciences) with an imidazole gradient in 50 mM Na 2 HPO 4 , 300 mM NaCl, 1 mM DTT, pH 7. Then, we dialyzed the protein against 50 mM Na 2 HPO 4 , 300 mM NaCl, 1 mM DTT, pH 7, and labeled it with Alexa488 maleimide.
Release of cytochrome c from isolated mitochondria. We isolated mouse liver mitochondria as described 53 (for details, see Supplementary Methods). We performed experiments of cyt c release with 60 µg of isolated mitochondria in AT buffer 53 supplemented with 5 mM succinate, 2 mM ATP, 10 µM phosphocreatine and 10 µg ml −1 creatine kinase. We incubated the indicated proteins for 1 h at 37 °C in a volume of 30 µl. We centrifuged the samples at 5,500g for 10 min at 4 °C. We checked the presence of cyt c in the pellets and supernatants by western blotting with a cyt c antibody (BD Biosciences).
Preparation of giant unilamellar vesicles. All lipids were from Avanti Polar Lipids. We prepared GUVs by the electroformation method. We spread 5 µl of lipid mixture at 1 mg ml −1 in chloroform on two Pt wire electrodes. We immersed the lipid films in a chamber containing 300 mM sucrose solution and connected the Pt wires to a power generator. We performed electroformation at 2.3 V and 10 Hz for 1 h at room temperature. We released the GUVs from the electrodes by changing the frequency to 2 Hz for 30 min.
Protein binding and membrane-permeabilization assays. We sedimented 50 µl of GUVs electroformed in 300 mM sucrose in 500 µl PBS containing the corresponding proteins. We added 16 nM of BCL XL ∆Ct green , 9 nM of tBID red and/or 290 nM unlabeled tBID, as indicated. After an ~2-h incubation at room temperature, we measured protein binding to the GUVs by confocal microscopy. We used an LSM 510 Meta microscope (Zeiss) with a 40× 1.2 NA C-Apochromat water objective (Zeiss) in the multitrack modus. We used UV/488/543/633 and 545 nm filters as main and secondary dichroics. The green channel consisted of an Ar laser with excitation wavelength at 488 nm and a 505-530-nm band-pass filter, whereas we configured the red channel with a 633-nm excitation laser and a 650-nm long-pass filter.
For the GUV permeabilization experiments, we added 5 µl of 50 µM Alexa543 free dye to GUV samples containing 16 nM BCL XL ∆Ct green and/or 9 nM tBID red and measured dye entrance into the GUVs with time. We imaged it in a different track with a 543-nm excitation laser and a 560-615-nm band-pass filter. After 4 h incubation at room temperature, we acquired images over a large area of the sample and counted the permeabilized and nonpermeabilized GUVs. We repeated all experiments at least three times and measured several hundreds of vesicles per experiment.
Fluorescence correlation spectroscopy. We performed FCS and FCCS measurements at 22 °C on a laser-scanning microscope (LSM) Meta 510 system (Carl Zeiss) using a 40× NA 1.2 UV-VIS-IR C Apochromat water-immersion objective, the 488-nm line of an Argon-ion laser (25 µW), the 633-nm HeNe laser (15 µW) and a home-built detection unit at the fiber output channel. We used a dichroic mirror and band-pass filters (D555, HQ520/40 and HQ700/75; AHF Analyze Technik) behind a collimating achromat to split the emission for the dual-color detection and to reject residual laser and background light. We then used achromats (LINOS Photonics) to image the internal pinhole onto the apertures of the fibers connected to the avalanche photodiodes (APD, PerkinElmer). We recorded the photon arrival times in the photon mode of the hardware correlator Flex 02-01D (http://correlator.com/).
For scanning FCS 29 , we repeatedly scanned the detection volume perpendicularly through the equator of a GUV. We controlled its movement directly with the Zeiss LSM operation software. We used the frame mode with Nx2 pixels to scan the two parallel lines. We measured their distance d by repeatedly scanning over a film of dried fluorophores and measuring the distance between the bleached traces in a high-resolution LSM image.
We performed data analysis with software written in MATLAB (MathWorks). For scanning FCS, we binned the photon stream in bins of 2 µs and arranged it as a matrix such that every row corresponded to one line scan. We corrected for movements of the membrane by calculating the position of the maximum of a running average over several hundred line scans and shifting it to the same column. We fitted an average over all rows with a Gaussian and we added only the elements of each row between −2.5σ and 2.5σ to construct the intensity trace. We computed the auto-and cross-correlation curves of the resulting intensity traces with a multiple tau correlation algorithm and fitted them with a nonlinear leastsquares fitting algorithm. In all FCS data processing, we excluded from further analysis irregular curves resulting from major instabilities and identified by distortions of the curves and a systematic change in the intensity trace. We fitted the resulting auto-and cross-correlation functions to analytical models as described in Supplementary Methods. We checked that the FCS analysis was not affected by dye quenching due to complex formation or oligomerization by fluorescence intensity distribution analysis (FIDA) in solution and by analyzing the counts per molecule of the fluorophores in membranes (see Supplementary Methods and Supplementary Fig. 5 ). 
